In this article
CIN2 Management and Active Surveillance
For moderate cervical lesions-abnormal cells on the surface of the cervix (commonly called cervical intraepithelial neoplasia grade 2 or CIN2), routine monitoring (“active monitoring”) rather than immediate treatment is recognized. The findings should help women and doctors make more informed choices.
CIN is divided into grade 1, 2 or 3 according to the severity of precancerous lesions, but CIN is not cervical cancer. It may progress to , but it may return to normal (degenerate) or remain unchanged. The diagnosis of CIN2 is currently the entry point for treatment. However, some studies have shown that CIN2 lesions usually resolve completely without treatment and should be actively monitored, especially young women, because treatment may be harmful to future pregnancy.
Spontaneous Regression Rates and Clinical Outcomes
The study analyzed the results of 36 studies involving 3,160 women diagnosed with CIN2 who had been actively monitored for at least three months. Two years later, 50% of the lesions resolved spontaneously, 32% persisted, and only 18% progressed to CIN3 or worse. Among women under the age of 30, the rate of degradation was higher (60%), 23% maintained, and 11% progressed.
Most CIN2 lesions, especially women younger than 30 years of age, will spontaneously degenerate, so active monitoring rather than immediate intervention is reasonable, especially for young women who may insist on monitoring. The chance of degradation is 50-60%, even if the risk of cancer is small (0.5% in this study), it is still possible. Surveillance only delays treatment, and some people still do not accept it. Other factors should also be considered including the effectiveness of treatment, the inconvenience of regular visits and the possibility of pregnancy complications.
The degradation rate of CIN2 is reassuring, but the degradation rate of CIN2 must be presented in a meaningful way and provide clear information about the effectiveness of monitoring and treatment so that women can make fully informed choices.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.